 DURHAM, NC ACCESSWIRE April 12, 2021 Heat Biologics, Inc. NASDAQ:HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021. PTX-35 is the companys first antibody-based product, currently in a Phase 1 clinical trial for the treatment of patients with solid tumors. 